Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases
Open Access
- 11 May 2021
- journal article
- letter
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 80 (10), 1357-1359
- https://doi.org/10.1136/annrheumdis-2021-220604
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- COVID-19 vaccination and antirheumatic therapyRheumatology, 2021
- Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?European Journal of Cancer, 2020
- COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseasesClinical and Experimental Immunology, 2020
- The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximabVaccine, 2011
- Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximabArthritis & Rheumatism, 2009
- Rituximab treatment results in impaired secondary humoral immune responsivenessBlood, 2002